




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61F 2/06</b>	<b>A1</b>	(11) International Publication Number: <b>WO 99/38455</b> (43) International Publication Date: <b>5 August 1999 (05.08.99)</b>
(21) International Application Number: <b>PCT/US98/08994</b> (22) International Filing Date: <b>4 May 1998 (04.05.98)</b> (30) Priority Data: <b>PCT/US98/02361 2 February 1998 (02.02.98) WO</b> (34) Countries for which the regional or international application was filed: <b>US et al.</b> (71) Applicant: <b>IMPRA, INC. [US/US]; 1625 West Third Street, P.O. Box 1740, Tempe, AZ 85280-1740 (US).</b> (72) Inventors: <b>McCREA, Brendan, J.; 4158 East Graythorn Avenue, Phoenix, AZ 85044 (US). EDWIN, Tarun, J.; P.O. Box 25118, Tempe, AZ 85285 (US). BANAS, Christopher, E.; 2524 North Alba Circle, Mesa, AZ 85213 (US).</b> (74) Agent: <b>BELUSKO, Vincent, J.; Graham &amp; James LLP, 14th floor, 801 S. Figueroa Street, Los Angeles, CA 90017-5554 (US).</b>	(81) Designated States: <b>AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b>  <b>Published</b> <i>With international search report.</i>	

(54) Title: **ENCAPSULATED INTRALUMINAL STENT-GRAFT AND METHODS OF MAKING SAME**

## (57) Abstract

Shape memory alloy and elastically self-expanding endoluminal stents which are at least partially encapsulated in a substantially monolithic expanded polytetrafluoroethylene ("ePTFE") covering. An endoluminal stent, which has a reduced diametric dimension for endoluminal delivery and a larger *in vivo* final diametric diameter, is encapsulated in an ePTFE covering which circumferentially covers both the luminal and abluminal walls along at least a portion of the longitudinal extent of the endoluminal stent. The shape memory endoluminal stent is fabricated from a shape memory alloy which exhibits either shape memory or pseudoelastic properties or from an elastic material having an inherent spring tension.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ENCAPSULATED INTRALUMINAL STENT-GRAFT AND METHODS OF MAKING SAME

### Cross-Reference to Related Applications

5           This application is a continuation-in-part of co-pending International patent application Serial No. PCT/US95/11817, filed 15 September 1995, which is a continuation-in-part of co-pending patent application Serial No. 08/401,871, filed March 10, 1995, both published as International Publication No. WO 96/28115, published September 19, 1996, and co-pending Internatioanl patent application Serial No. PCT/US98/02361, filed February 2, 1998, each of  
10       which is expressly incorporated by reference as if fully set forth herein.

### Background of the Invention

          The present invention relates generally to implantable intraluminal devices, particularly intraluminal stents. Because of the open lattice found in most intraluminal stents, a primary  
15       problem with these types of device is occlusion of the vessel occurring after stent placement. Tissue ingrowth and neointimal hyperplasia significantly reduces the open diameter of the treated lumen over time, requiring additional therapies. The present invention incorporates the use of a biocompatible barrier material that prevents or delays the tissue ingrowth and neointimal hyperplasia, thus maintaining luminal patency for longer periods after initial treatment. The use  
20       of expanded polytetrafluoroethylene (ePTFE) as a bio-inert barrier material is well documented. In accordance with certain of its preferred embodiments, the present invention utilizes a radially expandable ePTFE material, such as that described in co-pending International patent application Serial No. PCT/US98/02361, filed February 2, 1998, to partially or fully embed the stent lattice, thereby providing a suitable barrier which improves stent patency.

25           The inventive intraluminal stent-graft device may be implanted either by percutaneous delivery using an appropriate delivery system, a cut-down procedure in which a surgical incision is made and the intraluminal device implanted through the surgical incision, or by laparoscopic or endoscopic or endoscopic delivery. More particularly the present invention relates to shape memory alloy and self-expanding endoluminal stents which are at least partially encapsulated in  
30       a substantially monolithic expanded polytetrafluoroethylene ("ePTFE") covering. In accordance with the present invention, an endoluminal stent, which has a reduced diametric dimension for endoluminal delivery and a larger *in vivo* final diametric diameter, is encapsulated in an ePTFE

covering which circumferentially covers both the luminal and abluminal walls along at least a portion of the longitudinal extent of the endoluminal stent. The endoluminal stent is preferably fabricated from a shape memory alloy which exhibits either shape memory or pseudoelastic properties or from an elastic material having an inherent spring tension. In a first embodiment of the invention, the endoluminal stent is encapsulated in the ePTFE covering in the stent's reduced diametric dimension and is balloon expanded *in vivo* to radially deform the ePTFE covering. The endoluminal stent may be either one which exhibits thermal strain recovery, pseudoelastic stress-strain behavior or elastic behavior at mammalian body temperature. While in its reduced diametric dimension, the ePTFE encapsulating covering integrally constrains the endoluminal stent from exhibiting either thermal strain recovery, pseudoelastic stress-strain behavior or elastic behavior at mammalian body temperature. Radial deformation of the ePTFE covering releases constraining forces acting on the endoluminal stent by the undeformed ePTFE covering and permits the stent to radially expand. In a second embodiment of the invention, an endoluminal stent fabricated of a shape memory alloy is encapsulated in its final diametric dimension and the encapsulated intraluminal stent-graft is manipulated into its reduced diametric dimension and radially expanded *in vivo* under the influence of a martensite to austenite transformation. In a third embodiment of the present invention, a self-expanding intraluminal stent, fabricated of a material having an inherent spring tension, is encapsulated in its final diametric dimension and manipulated to a reduced diametric dimension and externally constrained for intraluminal delivery. Upon release of the external constraint *in vivo* the spring tension exerted by the self-expanding stent radially expands both the stent and the ePTFE encapsulating covering to a radially enlarged diameter. In a fourth embodiment of the invention, the endoluminal stent is fabricated from a material having an inherent elastic spring tension and it is encapsulated at a reduced dimension suitable for endoluminal delivery and balloon expanded *in vivo* to radially deform the ePTFE covering.

Shape memory alloys are a group of metallic materials that demonstrate the ability to return to a defined shape or size when subjected to certain thermal or stress conditions. Shape memory alloys are generally capable of being plastically deformed at a relatively low temperature and, upon exposure to a relatively higher temperature, return to the defined shape or size prior to the deformation. Shape memory alloys may be further defined as one that yields a thermoelastic martensite. A shape memory alloy which yields a thermoelastic martensite

undergoes a martensitic transformation of a type that permits the alloy to be deformed by a twinning mechanism below the martensitic transformation temperature. The deformation is then reversed when the twinned structure reverts upon heating to the parent austenite phase. The austenite phase occurs when the material is at a low strain state and occurs at a given temperature. The martensite phase may be either temperature induced martensite (TIM) or stress-induced martensite (SIM). When a shape memory material is stressed at a temperature above the start of martensite formation, denoted  $M_s$ , where the austenitic state is initially stable, but below the maximum temperature at which martensite formation can occur, denoted  $M_d$ , the material first deforms elastically and when a critical stress is reached, it begins to transform by the formation of stress-induced martensite. Depending upon whether the temperature is above or below the start of austenite formation, denoted  $A_s$ , the behavior when the deforming stress is released differs. If the temperature is below  $A_s$ , the stress-induced martensite is stable, however, if the temperature is above  $A_s$ , the martensite is unstable and transforms back to austenite, with the sample returning to its original shape. U.S. Patent Nos. 5,597,378, 5,067,957 and 4,665,906 disclose devices, including endoluminal stents, which are delivered in the stress-induced martensite phase of shape memory alloy and return to their pre-programmed shape by removal of the stress and transformation from stress-induced martensite to austenite.

Shape memory characteristics may be imparted to a shape memory alloy by heating the metal at a temperature above which the transformation from the martensite phase to the austenite phase is complete, *i.e.*, a temperature above which the austenite phase is stable. The shape of the metal during this heat treatment is the shape "remembered." The heat treated metal is cooled to a temperature at which the martensite phase is stable, causing the austenite phase to transform to the martensite phase. The metal in the martensite phase is then plastically deformed, *e.g.*, to facilitate its delivery into a patient's body. Subsequent heating of the deformed martensite phase to a temperature above the martensite to austenite transformation temperature, *e.g.*, body temperature, causes the deformed martensite phase to transform to the austenite phase and during this phase transformation the metal reverts back to its original shape.

The term "shape memory" is used in the art to describe the property of a material to recover a pre-programmed shape after deformation of a shape memory alloy in its martensitic phase and exposing the alloy to a temperature excursion through its austenite transformation temperature, at which temperature the alloy begins to revert to the austenite phase and recover

its preprogrammed shape. The term "pseudoelasticity" is used to describe a property of shape memory alloys where the alloy is stressed at a temperature above the transformation temperature of the alloy and stress-induced martensite is formed above the normal martensite formation temperature. Because it has been formed above its normal temperature, stress-induced  
5 martensite reverts immediately to undeformed austenite as soon as the stress is removed provided the temperature remains above the transformation temperature.

The martensitic transformation that occurs in the shape memory alloys yields a thermoelastic martensite and develops from a high-temperature austenite phase with long-range order. The martensite typically occurs as alternately sheared platelets, which are seen as a  
10 herringbone structure when viewed metallographically. The transformation, although a first-order phase change, does not occur at a single temperature but over a range of temperatures that varies with each alloy system. Most of the transformation occurs over a relatively narrow temperature range, although the beginning and end of the transformation during heating or cooling actually extends over a much larger temperature range. The transformation also exhibits hysteresis in that  
15 the transformations on heating and on cooling do not overlap. This transformation hysteresis varies with the alloy system.

A thermoelastic martensite phase is characterized by having a low energy state and glissile interfaces, which can be driven by small temperature or stress changes. As a consequence of this, and of the constraint due to the loss of symmetry during transformation, a thermoelastic  
20 martensite phase is crystallographically reversible. The herringbone structure of athermal martensite essentially consists of twin-related, self-accommodating variants. The shape change among the variants tends to cause them to eliminate each other. As a result, little macroscopic strain is generated. In the case of stress-induced martensite, or when stressing a self-accommodating structure, the variant that can transform and yield the greatest shape change  
25 in the direction of the applied stress is stabilized and becomes dominant in the configuration. This process creates a macroscopic strain, which is recoverable as the crystal structure reverts to austenite during reverse transformation.

The mechanical properties of shape memory alloys vary greatly over the transformation temperature range. Martensite phase alloys may be deformed to several percent strain at quite  
30 a low stress, whereas the austenite phase alloy has much higher yield and flow stresses. Upon

heating after removing the stress, the a martensite phase shape memory alloy will remember its unstrained shape and revert to its austenite phase.

Where a shape memory alloy is exposed to temperature above its transformation temperature, the martensite phase can be stress-induced. Once stress-induced martensite occurs, the alloy immediately strains and exhibits the increasing strain at constant stress behavior. Upon unloading of the strain, however, the shape memory alloy reverts to austenite at a lower stress and shape recovery occurs, not upon the application of heat but upon a reduction of stress. This effect, which causes the material to be extremely elastic, is known as pseudoelasticity and the effect is nonlinear.

The present invention preferably utilizes an binary, equiatomic nickel-titanium alloy because of its biocompatibility and that such an alloy exhibits a transformation temperature within the range of physiologically-compatible temperatures. Nickel-titanium alloys exhibit moderate solubility for excess nickel or titanium, as well as most other metallic elements, and also exhibits a ductility comparable to most ordinary alloys. This solubility allows alloying with many of the elements to modify both the mechanical properties and the transformation properties of the system. Excess nickel, in amounts up to about 1%, is the most common alloying addition. Excess nickel strongly depresses the transformation temperature and increases the yield strength of the austenite. Other frequently used elements are iron and chromium (to lower the transformation temperature), and copper (to decrease the hysteresis and lower the deformation stress of the martensite). Because common contaminants such as oxygen and carbon can also shift the transformation temperature and degrade the mechanical properties, it is also desirable to minimize the amount of these elements.

As used in this application, the following terms have the following meanings:

$A_f$  Temperature: The temperature at which a shape memory alloy finishes transforming to Austenite upon heating.

$A_s$  Temperature: The temperature at which a shape memory alloy starts transforming to Austenite upon heating.

Austenite: The stronger, higher temperature phase present in NiTi.

Hysteresis: The temperature difference between a phase transformation upon heating and cooling. In NiTi alloys, it is generally measured as the difference between  $A_p$  and  $M_p$ .

$M_f$  Temperature: The temperature at which a shape memory alloy finishes transforming to Martensite upon cooling.

$M_s$  Temperature: The temperature at which a shape memory alloy starts transforming to Martensite upon cooling.

5        Martensite: The more deformable, lower temperature phase present in NiTi.

Phase Transformation: The change from one alloy phase to another with a change in temperature, pressure, stress, chemistry, and/or time.

Shape Memory: The ability of certain alloys to return to a predetermined shape upon heating via a phase transformation.

10       Pseudoelasticity: The reversible non-linear elastic deformation obtained when austenitic shape memory alloys are strained at a temperature above the  $A_s$ , but below  $M_d$ , the maximum temperature at which pseudoelasticity is obtained.

Thermoelastic Martensitic Transformation: A diffusionless, thermally reversible phase transformation characterized by a crystal lattice distortion.

15

### **Summary of the Invention**

It is a principal objective of the present invention to encapsulate an intraluminal structural support with a substantially monolithic covering of ePTFE.

20       It is a further objective of the present invention to encapsulate a shape memory alloy intraluminal stent with a substantially monolithic covering of ePTFE.

It is another object of the present invention to provide a unique library of endoprotheses consisting generally of intraluminal structural supports made of shape memory alloys, which are at least partially encapsulated in a substantially monolithic expanded polytetrafluoroethylene covering, and which exhibit either thermal strain recovery, pseudoelastic stress-strain behavior or elastic behavior at mammalian body temperature.

25

It is a further objective of the present invention to encapsulate a shape memory alloy intraluminal stent at a reduced delivery diametric dimension and balloon expand the ePTFE encapsulated stent-graft to radially deform the ePTFE covering and release the radial constraint exerted by the ePTFE encapsulation on the shape memory stent thereby permitting the shape memory alloy stent to undergo transformation from its radially constrained dimension to an enlarged deployed dimension.

30



It is another objective of the present invention to encapsulate a shape memory alloy intraluminal stent at its enlarged diametric dimension, either with an at least partially unsintered tubular ePTFE extrudate having a diametric dimension comparable to the enlarged diametric dimension of the shape memory alloy intraluminal stent, or with a fully sintered ePTFE tubular member which has been radially expanded to a diametric dimension comparable to the enlarged diametric dimension of the shape memory alloy intraluminal stent and the encapsulated intraluminal stent is then reduced in its diametric dimension for endoluminal delivery.

It is yet a further objective of the present invention to encapsulate a self-expanding intraluminal stent, such as a GIANTURCO stent or a pseudoelastic shape memory stent, at a reduced delivery diametric dimension and balloon expand the ePTFE encapsulated stent-graft to radially deform the ePTFE covering and release the radial constraint exerted by the ePTFE encapsulation on the self-expanding stent thereby permitting the self-expanding stent to elastically radially expand to its *in vivo* diameter.

It is another objective of the present invention to encapsulate a self-expanding intraluminal stent at its enlarged diametric dimension, either with an at least partially unsintered tubular ePTFE extrudate having a diametric dimension comparable to the enlarged diametric dimension of the shape memory alloy intraluminal stent, or with a fully sintered ePTFE tubular member which has been radially expanded to a diametric dimension comparable to the enlarged diametric dimension of the self-expanding intraluminal stent and reducing the diametric dimension of the encapsulated stent for endoluminal delivery.

It is a still further objective of the present invention to encapsulate at a reduced delivery diametric dimension and balloon expand the ePTFE encapsulated stent-graft to radially deform the ePTFE covering and release the radial constraint exerted by the ePTFE encapsulation on the shape memory stent thereby permitting the stent to radially expand to a larger *in vivo* diametric dimension either by the shape memory property of the stent material or by elastic spring tension.

It is a further objective of the present invention to provide methods of encapsulating shape memory alloy intraluminal stents and self-expanding intraluminal stents, either at their reduced diametric dimension or at their *in vivo* diametric dimension.

It is another objective of the present invention to provide an ePTFE encapsulated intraluminal stent which is encapsulated between luminal and abluminal ePTFE tubular members,

where the ePTFE tubular members may be applied to the intraluminal stent in their unsintered, partially sintered or fully sintered state.

It is a further objective of the present invention to employ an ePTFE interlayer positioned adjacent either the luminal or the abluminal surface of the intraluminal stent as a bonding  
5 adjuvant interlayer between the luminal and abluminal ePTFE tubular members.

### **Brief Description of the Drawings**

Figure 1 is a perspective view of the ePTFE encapsulated intraluminal stent in accordance with the present invention.

10 Figure 2A is a perspective view of an ePTFE encapsulated intraluminal stent encapsulated at its reduced diametric dimension for intraluminal delivery and balloon assisted expansion *in vivo*.

Figure 2B is a perspective view of the ePTFE encapsulated intraluminal stent of Figure 2A illustrating the ePTFE encapsulated intraluminal stent after balloon assisted expansion.

15 Figure 3 is a side elevational, longitudinal cross-sectional view of the inventive ePTFE encapsulated intraluminal stent encapsulated at its nominal *in vivo* dimension.

Figure 4 is a side elevational, longitudinal cross-sectional view of the inventive ePTFE encapsulated stent of Figure 4, illustrating the ePTFE encapsulated intraluminal stent partially at a reduced intraluminal delivery diameter deformed to a relatively reduced diameter suitable  
20 for intraluminal delivery, mounted on a delivery catheter having an axially moveable constraining sheath which constrains the ePTFE encapsulated self-expanding intraluminal stent in its relatively reduced diametric dimension.

Figure 5 is a scanning electron micrograph, taken at 300X magnification, of an outer surface of the radially expanded ePTFE material used to encapsulate the balloon assisted radially  
25 expandable encapsulated NITINOL stent of the present invention.

Figure 6 is a scanning electron micrograph, taken at 300X magnification, of an inner surface of the ePTFE material used to encapsulate the balloon assisted radially expandable encapsulate NITINOL stent of the present invention.

Figure 7 is a scanning electron micrograph, taken at 300X magnification, of an outer  
30 surface of the ePTFE material used to encapsulate a self-expanding NITINOL or spring tension stent in accordance with the present invention.

Figure 8 is a scanning electron micrograph, taken at 300X magnification, of an inner surface of the ePTFE material used to encapsulate a self-expanding NITINOL or spring tension stent of the present invention.

Figure 9A is a flow diagram illustrating the inventive process steps to thermomechanically deform a pre-programmed shape memory stent to a reduced diametric dimension for encapsulation or endoluminal delivery.

Figure 9B is a flow diagram illustrating the inventive process steps to encapsulate a shape memory alloy stent and a self-expanding stent to make each preferred embodiment of the present invention.

### Detailed Description of the Preferred Embodiments

Figure 1 illustrates the ePTFE encapsulated intraluminal stent 10 of the present invention in a radially enlarged diametric dimension. The inventive ePTFE encapsulated intraluminal stent 10 of the present invention is best illustrated with reference to several preferred embodiments thereof. The first preferred embodiment is depicted in Figures 2A-2B and consists generally of an intraluminal stent 12 made of a shape memory alloy which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively smaller diametric dimension  $D_1$  and is radially expandable *in vivo* under the influence of a radially outwardly directed force which radially deforms the ePTFE covering 14 and releases the stress exerted on the intraluminal stent 12 while at body temperature to permit the intraluminal stent to undergo deformation to a larger diametric dimension  $D_2$ .

Figures 3-4 generically depict the second, third and fourth preferred embodiments of the present invention an intraluminal stent 20 which is at least partially encapsulated within a substantially monolithic ePTFE covering 14 over at least an entire circumferential portion of the luminal and abluminal surfaces of the intraluminal stent 12. The second, third and fourth preferred embodiments differ from one another based upon the type of intraluminal stent 20 utilized and whether the encapsulated stent device is intended to radially expand *in vivo* under the influence of the shape memory behavior or elastic spring tension behavior of the intraluminal stent 20 or whether *in vivo* delivery will be balloon catheter assisted.

The second preferred embodiment of the present invention consists generally of an intraluminal stent 20 made of a shape memory alloy which is at least partially encapsulated in a

substantially monolithic ePTFE covering 14 while in a relatively larger diametric dimension  $D_2$  and in the austenite phase, which is thermomechanically deformed at a temperature induced martensite phase and to a smaller diametric dimension  $D_1$  and constrained by a constraining sheath 22 for endoluminal delivery. Once at the delivery site, the external constraint 22 is removed and the intraluminal stent 20 undergoes martensitic transformation to the austenite state and thermoelastically deforms 24 to its predetermined shape while unfolding or decompressing, without plastically deforming, the ePTFE covering 14 into contact with the luminal tissue (not shown).

The third preferred embodiment of the present invention consists generally of a self-expanding intraluminal stent 20 made from either an elastic spring material or of a pseudoelastic shape memory material, and is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively small diametric dimension  $D_2$  such that the ePTFE encapsulating covering 14 acts to impart strain upon the intraluminal stent 20 and constrain the intraluminal stent from radial expansion to a relatively larger diametric dimension  $D_1$ , until intraluminally delivered and the ePTFE encapsulation radially deformed at body temperature to release the strain exerted by the ePTFE covering 14, thereby permitting the self-expanding intraluminal stent 20 to radially deform to a relatively larger diametric dimension.

The fourth preferred embodiment of the present invention consists generally of a self-expanding intraluminal stent 20 made from either an elastic spring material or a pseudoelastic shape memory material, which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively larger diametric dimension  $D_2$  such that the ePTFE encapsulating covering 14 restrains the intraluminal stent from further self-expansion. The assembly is then worked, such as by crimping, calendaring, folding, compressing or the like to reduce its diametric dimension to the reduced diametric dimension  $D_1$  suitable for endoluminal delivery and constrained by an external constraining sheath 22. Once positioned at a desired intraluminal site, the constraining sheath 22 is removed to release the constraining force and the intraluminal stent is permitted to elastically expand as denoted by arrows 24, carrying the ePTFE covering 14 into contact with the intraluminal tissue (not shown).

As will be illustrated by the following examples and the accompanying process flow diagrams at Figures 9A and 9B, the methods for making each of the foregoing embodiments differ with each preferred embodiment. The difference in the methods is largely due to the

selection of intraluminal stent type and whether the intraluminal encapsulated stent is intended for intraluminal delivery by balloon deformation of the ePTFE covering or whether delivery will occur due to the self-expanding property of the intraluminal encapsulated stent and non-deformation of the ePTFE covering.

5

### **First Embodiment**

In accordance with a first preferred embodiment, illustrated in Figures 2A and 2B, there is provided a balloon expandable encapsulated shape memory alloy intraluminal stent 10. The balloon expandable encapsulated shape memory alloy intraluminal stent 10 consists generally of an endoluminal stent 12 fabricated of a shape memory alloy, preferably one having an  $A_s$  value at a physiologically acceptable temperature compatible with tissue conservation, such as equiatomic nickel-titanium alloys known as NITINOL. The endoluminal stent 12 is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while the endoluminal stent 12 is in a relatively smaller diametric dimension  $D_1$ . The substantially monolithic ePTFE covering 14 is a continuous integral tubular structure, is free of seams and covers at least part of both the luminal and abluminal surfaces about an entire circumferential section of the endoluminal stent 12 along at least a portion of the longitudinal axis of the intraluminal stent 12. As illustrated in Figures 5 and 6, the substantially monolithic ePTFE covering 14 is characterized by having a node and fibril microstructure where the nodes are oriented generally perpendicular to the longitudinal axis 30 of the stent 12 and the fibrils are oriented generally parallel to the longitudinal axis 30 of the stent 12, with the distance between adjacent nodes being termed the "internodal distance." As more fully described in the parent application, published as International Application No. WO 96/28115, incorporated by reference, the substantially monolithic ePTFE covering 14 is preferably radially deformable at applied pressures less than about six atmospheres, most preferably less than about three atmospheres, due to the deformable nature of the nodes along their longitudinal axis, *i.e.*, radial relative to the substantially monolithic ePTFE covering 14 and perpendicular to the longitudinal axis 30 of the intraluminal stent 12. The encapsulated intraluminal stent 10 is radially expandable *in vivo* under the influence of a radially outwardly directed force, such as from a balloon catheter, which radially deforms the ePTFE covering to a second relative large diametric dimension,  $D_2$ , to release the constraining stress exerted on the intraluminal stent by the ePTFE covering while the

30

encapsulated intraluminal stent 10 is at body temperature. The simultaneous release of the constraining force exerted by the ePTFE covering permits the intraluminal stent 12 to undergo thermomechanical deformation to a larger diametric dimension.

## EXAMPLE 1

### BALLOON ASSISTED THERMALLY DEPLOYED STENT

A balloon assisted encapsulated shape memory alloy stent was constructed by longitudinally slitting about 5 cm of a 60 cm length of a first seamless unsintered expanded PTFE tube having an inner diameter of 3.0 mm. The slit ends were gripped into a fixture allowing the tube to hang vertically. At the opposite end of the tube, a length of wire was attached to assist in threading the tubing through the inner diameter of the stent. The thickness of the ePTFE layer was measured to be about 0.35 mm using a snap gauge. The ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the tube throughout the wall thickness of the ePTFE tube.

A 10 X 40 mm shape memory endoluminal stent was placed in a cold, dry environment at approximately -40° C and compressed about a mandrel having an outer diameter of 4.5 mm by mechanically deforming the stent to circumferentially conform to the outer diameter of the mandrel. The compressed stent was then removed from the cold, dry environment and concentrically passed over the outer diameter of the vertically hanging ePTFE tube, passing the wire through the stent lumen to assist in engaging the stent about the abluminal surface of the ePTFE tube without tearing or marring the ePTFE tube. A 3.3 mm diameter mandrel was then slid into the lumen of the ePTFE tube/stent assembly, and the tubing secured to the mandrel using ½ inch strips of tetrafluoroethylene (TFE) tape. The assembly was then removed from the vertical hanging fixture.

A 60 cm length of a second seamless partially sintered ePTFE tube, having an inner diameter of 4.3 mm, slightly larger inner diameter than the outer diameter of the first ePTFE tube to provide an interference fit between the first and second ePTFE tubes, was slit longitudinally in the same manner as described above, and placed in the vertical hanging fixture. The mandrel bearing the first ePTFE tube and the shape memory stent was then passed into the lumen of the second tube, until the stent was approximately centered on the mandrel. The wall thickness of the second layer was measured as described above, and the thickness was found to be about 0.35

mm. Again, as with the first, inner ePTFE layer, the fibrils were oriented parallel to the longitudinal axis of the tube. The ends of the second tube were also wrapped with strips of TFE tape to secure to the mandrel.

5 The assembly was then placed in a helical winding wrapping machine which tension wraps the assembly with a single overlapping layer of ½ inch TFE tape. The overlap of the winding was about 70%. The tension exerted by the TFE wrapping tape compresses the ePTFE/stent/ePTFE composite structure against the mandrel, thereby causing the layers of ePTFE to come into intimate contact through the interstices of the shape memory stent. The tension wrap was set to exert 1.7 psi pressure circumferentially around the ePTFE/stent/ePTFE and mandrel assembly.

10 The wrapped assembly was placed into a radiant heat furnace, which had been preheated to a 337° C set point. The assembly remained in the furnace for about 7 minutes, and was removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling the TFE helical wrap was unwound from the sample and discarded. The now ePTFE encapsulated stent assembly was then concentrically rotated about the axis of the mandrel to release any adhesion between the inner ePTFE layer and the mandrel. The ePTFE encapsulated stent assembly, still on the mandrel, was placed into a laser trimming fixture to trim excess ePTFE materials away from the proximal and distal ends. After trimming, the trimmed encapsulated stent was removed from the mandrel.

20 Five encapsulated stent samples were prepared in accordance with the foregoing description and were each placed a balloon on a 10 mm by 4 cm PTA balloon dilation catheter. The device was then placed into a temperature controlled water bath maintained at 37° C. The balloon was pressurized using a saline filled inflator, thereby expanding the encapsulated stent. Each encapsulated stent device was radially expanded under the influence of balloon deformation of the ePTFE encapsulating covering with full radial deformation to a 10 mm inner diameter occurring at inflation pressures between 2 and 4 atmospheres.

## EXAMPLE 2

### THIN WALL THERMALLY DEPLOYED STENT

5 The radially expanded encapsulated stents obtained from Example 1 were placed over a 10 mm diameter stainless steel mandrel, and spiral wrapped using ½ inch ePTFE tape as described above.

10 The wrapped assembly was placed again into a radiant heat furnace, which had been preheated to 337° C set point. The assembly remained in the furnace for about 10 minutes, and was removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After air cooling, the ends of the mandrel was engaged in two rings and the TFE helical wrap was unwound from the encapsulated stent samples and discarded. The encapsulated stents were concentrically rotated about the axis of the mandrel to release adhesion between the luminal ePTFE surface of the encapsulated stent and the mandrel.

15 The encapsulated stent was next cooled to about -20 °C in a cold dry environment and allowed to equilibrate for 30 minutes. The cooled encapsulated stent was then rolled between 2 plates to successively reduce the encapsulated stent inner diameter to about 3.5 mm, representing a reduction of about 40% from the radially expanded inner diameter of the encapsulated stent. The encapsulated stent at the reduced inner diameter of 3.5 mm was fully inserted into a constraining sheath having an inner diameter of approximately 3.7 mm.

20 The externally constrained encapsulated stent was then removed from the cold environment, and placed into a water bath maintained at a temperature of 37° C. A pusher rod was inserted into the constraining sheath and impinged upon one end of the constrained encapsulated stent. By passing the pusher rod through the constraining sheath, the encapsulated stent was ejected from constraining sheath. As the stent was ejected, it radially dilated from its compressed state, and re-assumed the original fully expanded diametric dimension of about 10 mm inner diameter.

### Second Embodiment

30 The second preferred embodiment of the present invention, depicted in Figures 3-4, consists generally of an intraluminal stent 20 made of a shape memory alloy which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively larger diametric dimension  $D_2$  and in the austenite phase, which is thermomechanically deformed to a



temperature induced martensite phase and to a smaller diametric dimension  $D_1$  and constrained by constraining sheath 22 for endoluminal delivery. Once at the delivery site, the constraint 22 is removed and the intraluminal stent 20 undergoes martensitic transformation to the austenite state and thermoelastically deforms 24 to its enlarged diametric dimension  $D_2$  while unfolding the ePTFE covering 14 into contact with the luminal tissue (not shown).

### EXAMPLE 3

#### THERMALLY SELF-DEPLOYING ENCAPSULATED STENT

A thermally deployed encapsulated shape memory alloy stent was constructed by placing a 40 cm length of a first seamless expanded PTFE tube over a 10 mm cylindrical stainless steel mandrel. The inner diameter of the ePTFE tube was of a sufficient size to permit an interference fit with the mandrel. The thickness of the ePTFE layer was measured to be about 0.20 mm by taking a radial slice of the seamless tube, and evaluated by light microscopy incorporating a calibrated reticle. The ePTFE tube has a node-fibril microstructure in which the fibrils are oriented perpendicular to the longitudinal axis of the mandrel throughout the wall thickness of the ePTFE tube. The ends of the ePTFE tube were wrapped with TFE tape to keep the tube from sliding along the mandrel for the next assembly step. A shape memory alloy stent having a nominal inner diameter of about 10 mm and being about 100 mm in length in its enlarged diametric configuration was concentrically placed over the ePTFE covered mandrel at about 22° C and positionally centrally along the longitudinal length of the ePTFE tube. The inner diameter of the shape memory stent was toleranced to the outer diameter of the ePTFE tube on the mandrel and engaged about the ePTFE tube without tearing or disturbing the surface of the ePTFE tube. A second seamless ePTFE tube having a wall thickness of 0.20 mm, measured as described above, was concentrically engaged over the stent and the first ePTFE tube by first making diametrically opposed longitudinal slits in one end of the second ePTFE tube and concentrically inserting the mandrel/first ePTFE tube/stent assembly into the lumen of the second tube. Again, as with the first ePTFE tube, the second ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the second ePTFE tube throughout the wall thickness of the second ePTFE tube. The opposing ends of the second ePTFE tube were secured about the first ePTFE tube and the mandrel by tension wrapping with strips of TFE tape.

The entire assembly was then placed in a helical winding tension wrapping machine which tension wrapped the assembly with a single overlapping layer of ½ inch TFE tape in the same manner as in Example 1 to compress the ePTFE material from the first and second ePTFE tubes into intimate contact with one another through the wall openings of the stent.

5       The wrapped assembly was placed into a radiant heat furnace, which had been preheated to about a 337° C set point. The assembly remained in the furnace for about 10 minutes, and was removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling, the ends of the mandrel were engaged in two rings and the TFE helical wrap was unwound from the encapsulated stent assembly and  
10       discarded. The encapsulated stent assembly was then circumferentially rotated about the axis of the mandrel to break any adhesion occurring between the luminal ePTFE material and the mandrel. Excess ePTFE material from the proximal and distal ends of the encapsulated stent assembly was then laser trimmed in the manner described in Example 1 and the encapsulated stent assembly was removed from the mandrel.

15       The encapsulated stent was then cooled to about -20°C in a cold dry environment and allowed to equilibrate for 30 minutes. The encapsulated stent was then flattened between 2 plates to bring diametrically opposed luminal wall surfaces of the encapsulated stent into contact with one another, thereby creating a flat structure without an inner lumen. The encapsulated stent was then folded over itself along its longitudinal axis once, and then again for a total of one flattening  
20       operation and two folding operations. Thus, the diameter of the embedded stent was reduced about 60% from its original post encapsulated diameter. While still in the cold, dry environment, the device was fully inserted into a constraining sheath with an internal diameter of approximately 4.7 mm.

25       The folded and sheathed stent was then removed from the cold environment, and placed into a water bath maintained at a temperature of 37°C. A pusher was inserted into the lumen of the constraining sheath and the encapsulated stent was ejected from the constraining sheath as described above in Example 2. As the stent was ejected, it unfolded from its flattened and folded state, and re-assumed the original tubular diametric configuration having a nominal inner  
30       diameter of 10 mm.

**Third Embodiment**

The third preferred embodiment of the present invention, depicted in Figures 2A-2B, and consists generally of self-expanding intraluminal stent 10 made from either an elastic spring material or of a pseudoelastic shape memory material, and is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively small diametric dimension  $D_1$  such that the ePTFE encapsulating covering 14 acts to impart strain upon the intraluminal stent 10 and constrain the intraluminal stent 10 from radial expansion to a relatively larger diametric dimension  $D_2$ . Until it is intraluminally delivered and the ePTFE encapsulation 14 radially deformed at body temperature to release the strain exerted by the ePTFE covering 14 the self-expanding intraluminal stent 10 cannot radially deform to a relatively larger diametric dimension  $D_2$ .

**EXAMPLE 4****ELASTIC SPRING BALLOON DEPLOYED ENCAPSULATED STENT**

An encapsulated elastically self-expanding stainless steel stent was constructed by placing a 30 cm length of seamless unsintered ePTFE tube over a 3.3 mm cylindrical stainless steel mandrel. The inner diameter of the ePTFE tube was toleranced to provide a slight interference fit to the mandrel. The thickness of the ePTFE layer was measured to be about 0.35 mm by direct measurement of seamless tube wall using a snap gauge. The ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis ePTFE tube throughout the wall thickness of the ePTFE tube. The ends of the ePTFE tube were wrapped with strips of TFE tape to retain the position of the ePTFE tube on the mandrel for the next assembly step. A second seamless sintered ePTFE tube was concentrically engaged over the first ePTFE tube by first longitudinally slitting opposing ends of the ends of the second tube, then inserting the mandrel and first ePTFE tube into the lumen of the second ePTFE tube. One end of the second ePTFE was wrapped with strips of 1/2 inch TFE tape to secure it to the first ePTFE tube and the mandrel. The wall thickness of the second layer was measured as described above, and the thickness was found to be about 0.35 mm. As with the first ePTFE tube, the second ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the ePTFE tube.

An elastic spring stainless steel stent having a nominal inner diameter of about 15 mm and a length of about 24 mm in its enlarged diametric configuration was inserted into a constraining sheath to reduce the inner diameter to about 4.0 mm. A small length of the stent is left exposed

from one end of the constraining sheath. The constraining sheath containing the radially constrained stent was inserted over the mandrel, and forced between the first and second ePTFE tubes such that it was positioned intermediate to the first and second ePTFE tubes. The exposed end of the stent was then frictionally engaged through the second ePTFE tube wall and the constraining sheath retracted, leaving the stent positioned between the first and second ePTFE tubes. The unsecured end of the second ePTFE tube was then secured to the first ePTFE tube and the mandrel with strips of ½ inch TFE tape.

The assembly was then placed in a helical winding machine to tension wrap a single overlapping layer of ½ inch TFE tape, and sintered in a radiant heat furnace, cooled, the TFE tape unwrapped and the excess ePTFE laser trimmed as described in Example 1 above.

The resulting encapsulated stent was placed over the balloon on a 12 mm by 4 cm PTA balloon dilation catheter. The device was then placed into a temperature controlled water bath maintained at 45° C. The balloon was pressurized using a saline filled inflator which radially deformed the ePTFE encapsulation and permitted radial expansion of the elastically self-expanding stent. The encapsulated stent fully radially expanded to a 12 mm inner diameter at an applied pressure of 2.5 atmospheres.

#### **Fourth Embodiment**

The fourth preferred embodiment of the present invention, also representatively depicted in Figures 3-4, consists generally of a self-expanding intraluminal stent 20 made from either an elastic spring material or a pseudoelastic shape memory material, which is at least partially encapsulated in a substantially monolithic ePTFE covering 14 while in a relatively larger diametric  $D_2$  dimension such that the ePTFE encapsulating covering 14 acts as to restrain the intraluminal stent 20 from further self-expansion. The encapsulated assembly is then worked, such as by crimping, calendaring, folding, or the like, to its reduced diametric dimension  $D_1$  to achieve a profile suitable for endoluminal delivery and the assembly is then constrained by an external constraining sheath 22. Once positioned at a desired intraluminal site, the constraining sheath 22 is removed to release the constraining force and the intraluminal stent 20 is permitted to elastically expand 24, carrying the ePTFE covering 14 into contact with the intraluminal tissue (Not shown).

**EXAMPLE 5****STRESS-INDUCED MARTENSITE SELF-DEPLOYING ENCAPSULATED STENT**

5 A self deploying encapsulated shape memory alloy stent is constructed by placing a 40 cm length of seamless expanded PTFE tube over a 10 mm cylindrical stainless steel mandrel. The inner diameter of the ePTFE tube is closely toleranced to provide a slight interference fit to the mandrel. The thickness of the ePTFE layer is measured to be about 0.20 mm by taking a radial slice of the seamless tube, and evaluated by light microscopy incorporating a calibrated reticle. The tubing is constructed such that the fibrils are oriented perpendicular to the longitudinal axis  
10 of the mandrel. The ends of the seamless tube are wrapped with strips of TFE tape to keep the tube from sliding along the mandrel for the next assembly step. A shape memory alloy stent about 10 mm inner diameter by 100 mm in length in its enlarged diametric configuration is placed over the ePTFE covered mandrel at about 22° C and centered over the ePTFE layer. The inner diameter of the shape memory stent is closely toleranced to the outer diameter of the ePTFE covered mandrel. A second tube of seamless expanded PTFE is placed over the stent by slitting  
15 the ends of the second tube, and inserting the mandrel, ePTFE tube, and stent assembly into the second tube. The wall thickness of the second layer is measured as described above, and the thickness is found to be about 0.20 mm. Again, as with the first, inner ePTFE layer, the fibrils are oriented perpendicular to the longitudinal axis of the mandrel. The ends of the second tube are also wrapped with strips of TFE tape.  
20

The assembly is then placed in a helical winding machine which wraps the assembly with a single overlapping layer of ½ inch TFE tape. The overlap of the winding was about 70%. The wrapping material compresses the ePTFE/Stent/ePTFE composite structure against the mandrel, causing the layers of ePTFE to come into intimate contact through the interstices of the shape  
25 memory stent.

The wrapped assembly is placed into a radiant heat furnace, which is preheated to a 337° C set point. The assembly remains in the furnace for about 10 minutes, and removed. The heated assembly is allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling, the ends of the mandrel are engaged in two rings, allowing the TFE  
30 helical wrap to be unwound from the sample and discarded. The ePTFE/Stent assembly is then rotated about the axis of the mandrel to break the grip of the inner ePTFE layer to the mandrel. The stent sample, while still on the mandrel, is placed into a fixture to allow for laser trimming of the ePTFE materials away from the embedded stent. Trimming operation is performed on

both ends of the device. After trimming, the embedded and trimming stent was removed from the mandrel.

The encapsulated stent is then rolled between 2 plates, reducing the diameter of the stent to about 3.5 mm. Thus the diameter of the embedded stent is reduced about 40% from its original post encapsulated diameter. While in the compressed state, the device is fully inserted into a constraining sheath with an internal bore of approximately 3.7 mm.

The constrained stent is placed into a water bath maintained at a temperature of 37° C. A pusher was inserted into the bore of the sheath, and the stent ejected from the constraining sheath. As the stent was ejected, it unfurled from its flattened and folded state, and re-assumed the original post encapsulation tubular diametric configuration.

### **Fifth Embodiment**

In accordance with a fifth preferred embodiment of the inventive encapsulated stent, an at least partially unsintered tubular interlayer is interdisposed between the inner and outer ePTFE layers and adjacent the intraluminal stent along at least a longitudinal extent thereof. The interlayer member may consist of a single tubular member which extends along at least a portion of the longitudinal axis of the intraluminal stent. Alternatively, the interlayer member may consist of a plurality of ring-like members positioned along the longitudinal axis of the intraluminal stent and in spaced-apart relationship from one and other. The interlayer member is may be preferably employed either i) where at least one of the inner and outer ePTFE tubular members of the inventive encapsulated intraluminal stent is fully sintered to formation of a monolithic joining of the inner and outer ePTFE tubular members, and/or ii) to serve as a barrier between a radiopaque marker and the intraluminal stent to insulate against galvanic corrosion resulting from contact of metal atoms in a radiopaque marker and metal in an intraluminal stent.

The interlayer member may be employed with any type of intraluminal stent, i.e., a shape memory alloy which behaves in either a thermoelastic or pseudoelastic manner, with a self-expanding stent in which radial expansion is a spring tension mediated event, or with a balloon expandable stent.

### **EXAMPLE 6**

#### **THERMALLY SELF-DEPLOYING ENCAPSULATED STENT**

A thermally deployed encapsulated shape memory alloy stent was constructed by placing a 40 cm length of a first sintered seamless expanded PTFE tube over a 10 mm cylindrical

stainless steel mandrel. The inner diameter of the ePTFE tube was of a sufficient size to permit an interference fit with the mandrel. The thickness of the ePTFE layer was measured to be about 0.20 mm by taking a radial slice of the seamless tube, and evaluated by light microscopy incorporating a calibrated reticle. The ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the mandrel throughout the wall thickness of the ePTFE tube. The ends of the ePTFE tube were wrapped with TFE tape to keep the tube from sliding along the mandrel for the next assembly step. A shape memory alloy stent having a nominal inner diameter of about 10 mm and being about 100 mm in length in its enlarged diametric configuration was concentrically placed over the ePTFE covered mandrel at about 22° C and positionally centrally along the longitudinal length of the ePTFE tube. The inner diameter of the shape memory stent was toleranced to the outer diameter of the ePTFE tube on the mandrel and engaged about the ePTFE tube without tearing or disturbing the surface of the ePTFE tube.

A pair of unsintered ePTFE rings, prepared by wrapping unsintered ePTFE films concentrically about each of the opposing ends of the shape memory alloy stent and the first sintered ePTFE tube, such that the node and fibril microstructure of the unsintered ePTFE rings had a fibril orientation perpendicular to the fiber orientation of the first ePTFE tube and the longitudinal axis of the stent.

A second sintered seamless ePTFE tube having a wall thickness of 0.20 mm, measured as described above, was concentrically engaged over the entire length of the stent, the pair of unsintered ePTFE rings and the first ePTFE tube by first making diametrically opposed longitudinal slits in one end of the second ePTFE tube and concentrically inserting the mandrel/first ePTFE tube/stent assembly into the lumen of the second tube. Again, as with the first ePTFE tube, the second ePTFE tube has a node-fibril microstructure in which the fibrils are oriented parallel to the longitudinal axis of the second ePTFE tube throughout the wall thickness of the second ePTFE tube. The opposing ends of the second ePTFE tube were secured about the first ePTFE tube and the mandrel by tension wrapping with strips of TFE tape.

The entire assembly was then placed in a helical winding tension wrapping machine which tension wrapped the assembly with a single overlapping layer of 1/2 inch TFE tape in the same manner as in Example 1 to compress the ePTFE material from the first and second ePTFE tubes into intimate contact with one another through the wall openings of the stent.

The wrapped assembly was placed into a radiant heat furnace, which had been preheated to about a 337° C set point. The assembly remained in the furnace for about 10 minutes, and was

removed. The heated assembly was allowed to cool for a period of time sufficient to permit manual handling of the assembly. After cooling, the ends of the mandrel were engaged in two rings and the TFE helical wrap was unwound from the encapsulated stent assembly and discarded. The encapsulated stent assembly was then circumferentially rotated about the axis of the mandrel to break any adhesion occurring between the luminal ePTFE material and the mandrel. Excess ePTFE material from the proximal and distal ends of the encapsulated stent assembly was then laser trimmed in the manner described in Example 1 and the encapsulated stent assembly was removed from the mandrel.

The encapsulated stent was then cooled to about -20°C in a cold dry environment and allowed to equilibrate for 30 minutes. The encapsulated stent was then flattened between 2 plates to bring diametrically opposed luminal wall surfaces of the encapsulated stent into contact with one another, thereby creating a flat structure without an inner lumen. The encapsulated stent was then folded over itself along its longitudinal axis once, and then again for a total of one flattening operation and two folding operations. Thus, the diameter of the embedded stent was reduced about 60% from its original post encapsulated diameter. While still in the cold, dry environment, the device was fully inserted into a constraining sheath with an internal diameter of approximately 4.7 mm.

The folded and sheathed stent was then removed from the cold environment, and placed into a water bath maintained at a temperature of 37°C. A pusher was inserted into the lumen of the constraining sheath and the encapsulated stent was ejected from the constraining sheath as described above in Example 2. As the stent was ejected, it unfolded from its flattened and folded state, and re-assumed the original tubular diametric configuration having a nominal inner diameter of 10 mm.

While the interlayer member employed in the foregoing Example 6 was a sheet of unsintered ePTFE material, it will also be appreciated that tubular or ring-like unsintered ePTFE members may be employed. Where the interlayer member is a tubular or ring-like unsintered ePTFE member, the interlayer member will preferably have a node and fibril microstructure in which the fibril orientation of the interlayer member is parallel to the longitudinal axis of the interlayer member and parallel with the fibril orientation of the inner and outer ePTFE tubular members which the interlayer member is interdisposed between. This co-parallel arrangement of the fibril orientations of the interlayer member and the inner and outer ePTFE tubular members permits the resulting encapsulated stent device to be further radially expanded by balloon expansion in order to further model the *in vivo* profile to the receiving anatomical



structure at radial expansion pressures comparable to that of the balloon assisted encapsulated stent embodiments described above.

Where a thermoelastic transformation of a shape memory intraluminal stent is desired, care must be taken to 1) avoid imparting a secondary shape memory to the shape memory alloy during sintering of the ePTFE encapsulating covering, 2) avoid inducing stress-induced martensite formation during thermomechanical forming for either encapsulation or mounting onto a delivery catheter, and 3) avoid inducing non-recoverable strains by exceeding the strain limit of the shape memory alloy material used. Where the elastic behavior of a stent made of either a pseudoelastic shape memory alloy or a spring tension material, care must be taken to avoid plastically deforming the stent which would deleteriously effect the elastic deformation property of the intraluminal stent during intraluminal delivery. Finally, where the pseudoelastic behavior of an intraluminal stent made of a shape memory material is to be utilized in the encapsulated intraluminal stent, care must be taken to maintain the temperature of the shape memory alloy above  $A_s$ , but below  $M_s$  during either the process of encapsulating the stent at a reduced diameter, and before sintering, for balloon expansion *in vivo* or during deformation of the encapsulated stent to a reduced delivery diameter for loading onto a delivery catheter. In this manner, the stress-induced martensite phase will be induced in the shape memory alloy during deformation of the stent to a diametric dimension suitable for endoluminal delivery and maintained so that when the encapsulated stent, in the stress-induced martensite state is delivered and either the ePTFE constraint or the constraining sheath is relieved, the strain is released and the stent, in the stress-induced martensite phase is permitted to transform to austenite and the stent to elastically deform to its pre-programmed diametric dimension.

The methods described in the foregoing Examples are summarized in Figures 9A-9B, which are process flow diagrams setting forth the fundamental method steps of the methods to make each of the above-described preferred embodiments. Where a shape memory intraluminal stent is to be encapsulated in an ePTFE covering, and thermoelastic transformation of the shape memory stent is desired, either in a balloon assisted expandable encapsulated stent embodiment or in a self-expanding encapsulated stent embodiment, the thermoelastic deformation of the shape memory stent from its enlarged diametric dimension  $D_2$  to its reduced diametric dimension  $D_1$  may be accomplished in accordance with the method 40 set forth in Figure 9A. Thermoelastic deformation method 40 entails first providing an shape memory alloy intraluminal stent having a predetermined shape memory configuration 42. The intraluminal stent is then exposed to a temperature below the martensite transformation temperature  $M_s$  of the shape memory alloy 44

and allowed to equilibrate at the sub-martensite transformation temperature  $M_s$ . While still below the  $M_s$  temperature, the stent is mechanically deformed to reduce its diameter from the enlarged diametric dimension  $D_2$  to a reduced diametric dimension  $D_1$  suitable for endoluminal delivery. The stent at its reduced diametric dimension is now at a dimensional state suitable for encapsulation at its reduced diametric dimension  $D_1$ .

The encapsulation method 60 is more fully set forth in Figure 9B, and is applicable for either a shape memory alloy intraluminal stent which is to be encapsulated either at its reduced diametric dimension  $D_1$  or at its enlarged diametric dimension  $D_2$ , as well as for a self-expanding stent which radially expands due to inherent spring tension in the stent. A luminal ePTFE tube 62 is concentrically engaged upon a mandrel 64 and secured to the mandrel. Either a shape memory stent or a self-expanding stent is selected at step 66. If a shape memory stent is selected 70, the shape memory stent 52 is engaged over the luminal ePTFE tube at step 54 while maintaining the stent at a temperature below  $A_s$  to prevent the stent from radially expanding. If a self-expanding stent is selected 68, an abluminal ePTFE tube is concentrically engaged over the luminal ePTFE tube and the self-expanding stent 80 interdisposed between the luminal and abluminal ePTFE tubes and secured there between 78. Where a shape memory alloy intraluminal stent is employed 74, the abluminal ePTFE tube is concentrically engaged over the stent. Once the stent is positioned intermediate between the luminal and abluminal ePTFE tubes, the entire assembly is then wrapped with TFE tape 82 to exert a circumferential pressure about the entire circumference of both the luminal and abluminal ePTFE tubes and the stent, causing the ePTFE tubes to be motivated into intimate contact with one and other through the interstices of the stent. The entire wrapped assembly is then sintered 84 and excess ePTFE overlaying ends of the stent may be trimmed 86.

Once trimmed, the encapsulated stent is then prepared for mounting onto a delivery catheter 88, either by mounting the encapsulated stent in its reduced diametric dimension  $D_1$  onto a balloon catheter for balloon-assisted delivery, or by thermomechanical deformation from the enlarged diametric dimension  $D_2$  to the reduced diametric dimension  $D_1$  following the method steps of thermomechanical deformation 40 or formation of stress-induced martensite for pseudoelastic recovery by crimping, folding or otherwise reducing the encapsulated stent to its reduced diametric dimension  $D_1$ , mounting onto a delivery catheter and applying an external constraining sheath concentrically over the encapsulated stent.

Those skilled in the art will understand and appreciate that while the present invention has been described with reference to its preferred embodiments and the examples contained

herein, certain variations in material composition, shape memory alloy constitution, stent and ePTFE dimensional size and configuration, temperatures, times and other operational and environmental conditions may be made without departing from the scope of the present invention which is limited only by the claims appended hereto. For example, one skilled in the art will

5 understand and appreciate from the foregoing that the methods for making each of the foregoing embodiments differs with each preferred embodiment. These differences in the methods are largely due to the selection of intraluminal stent type and whether the intraluminal encapsulated stent is intended for intraluminal delivery by balloon expansion or whether delivery will occur due to the self-expanding property of the intraluminal encapsulated stent.

10

**What is Claimed is:**

1. An endoluminal prosthesis, comprising:  
an endoluminal stent made of a shape memory material, the endoluminal stent having an at least substantially austenite dimensional state whereby the endoluminal stent assumes a generally tubular conformation defining a central longitudinal lumen delimited by walls of the endoluminal stent, the walls having luminal and abluminal surfaces thereof; and  
a monolithic expanded polytetrafluoroethylene layer forming a continuous circumferential covering over at least a portion of the longitudinal axis of each of the luminal and abluminal surfaces of the endoluminal stent walls circumferentially enclosing at least a portion of the central longitudinal lumen of the endoluminal stent, the expanded polytetrafluoroethylene layer having a node and fibril microstructure wherein the fibrils have a generally uniaxial orientation throughout the monolithic expanded polytetrafluoroethylene layer.
2. The endoluminal prosthesis according to Claim 1, wherein the shape memory stent further comprises a nickel-titanium alloy.
3. The endoluminal prosthesis according to Claim 2, wherein the nickel-titanium alloy further comprises an alloy consisting essentially of nickel present at about 50 at. %, titanium present at about 50 at. %.
4. The endoluminal prosthesis according to Claim 1, wherein the monolithic expanded polytetrafluoroethylene layer further comprises a luminal and an abluminal layer of expanded polytetrafluoroethylene tubular material intimately joined to one another through the walls of the endoluminal stent.
5. The endoluminal prosthesis according to Claim 1, wherein the monolithic expanded polytetrafluoroethylene layer encapsulates the endoluminal stent in a reduced diametric dimension suitable for endoluminal delivery.
6. The endoluminal prosthesis according to Claim 4, wherein the luminal and an abluminal layers of expanded polytetrafluoroethylene tubular material further comprise radially pre-expanded microporous polytetrafluoroethylene tubular members and the endoluminal stent

made of a shape memory material is substantially encapsulated at an enlarged diametric dimension.

5        7.        The endoluminal prosthesis according to Claim 4, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene material further comprise expanded polytetrafluoroethylene tubular members extruded at a diametric dimension sufficient to substantially encapsulate the endoluminal stent at its austenite dimensional state.

10       8.        The endoluminal prosthesis according to any of claims 1 to 7, wherein the shape memory material comprising the endoluminal stent further comprises a pseudoelastic shape memory alloy.

9.        An endoluminal prosthesis, comprising:  
an endoluminal stent made of a material having an elastic spring tension having a  
15       generally tubular conformation defining a central longitudinal lumen delimited by walls of the endoluminal stent, the walls having luminal and abluminal surfaces thereof, the endoluminal stent having a first dimensional state whereby the endoluminal stent is radially constrained for endoluminal delivery into a body and a second dimensional state whereby the elastic spring tension is released and the endoluminal stent elastically deforms into contact with endoluminal  
20       tissue; and

a monolithic expanded polytetrafluoroethylene layer forming a continuous circumferential covering over each of the luminal and abluminal surfaces of the endoluminal stent walls circumferentially enclosing at least a portion of the central longitudinal lumen of the endoluminal stent.

25       10.       The endoluminal prosthesis according to Claim 9, wherein the monolithic expanded polytetrafluoroethylene layer further comprises a luminal and an abluminal layer of expanded polytetrafluoroethylene tubular material intimately joined to one another through the walls of the endoluminal stent.

30       11.       The endoluminal prosthesis according to Claim 10, wherein the luminal and an abluminal layers of expanded polytetrafluoroethylene tubular material further comprise radially pre-expanded microporous polytetrafluoroethylene tubular members.

12. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene tubular material further comprise polytetrafluoroethylene tubular members extruded at a diametric dimension sufficient to substantially encapsulate the endoluminal stent at an enlarged diametric dimension.

13. The endoluminal prosthesis according to Claim 12, wherein the abluminal polytetrafluoroethylene tubular member is extruded at a diametric dimension greater than that required to encapsulate the abluminal wall of the endoluminal stent.

14. The endoluminal prosthesis according to Claim 10, wherein the luminal and an abluminal layers of expanded polytetrafluoroethylene tubular material further comprise microporous polytetrafluoroethylene tubular members radially expandable under the influence of a radially outwardly directed pressure less than about six atmospheres.

15. The endoluminal prosthesis according to Claim 10, wherein the luminal and an abluminal layers of expanded polytetrafluoroethylene tubular material further comprise microporous polytetrafluoroethylene tubular members radially expandable under the influence of a radially outwardly directed pressure less than about five atmospheres.

16. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene material further comprise microporous polytetrafluoroethylene tubular members radially expandable under the influence of a radially outwardly directed pressure less than about four atmospheres.

17. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene material further comprise radially expandable microporous polytetrafluoroethylene tubular members and the endoluminal prosthesis is radially expandable in vivo under the influence of a radially outwardly directed pressure applied from the central longitudinal lumen of the endoluminal prosthesis less than about six atmospheres.

18. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene material further comprise radially expandable microporous polytetrafluoroethylene tubular members and the endoluminal prosthesis is radially expandable in vivo under the influence of a radially outwardly directed pressure applied from the central longitudinal lumen of the endoluminal prosthesis less than about five atmospheres.

19. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene material further comprise radially expandable microporous polytetrafluoroethylene tubular members and the endoluminal prosthesis is radially expandable in vivo under the influence of a radially outwardly directed pressure applied from the central longitudinal lumen of the endoluminal prosthesis less than about 4.5 atmospheres.

20. The endoluminal prosthesis according to Claim 10, wherein the luminal and abluminal layers of expanded polytetrafluoroethylene further comprise radially expandable microporous polytetrafluoroethylene tubular members and the endoluminal prosthesis is radially expandable in vivo under the influence of a radially outwardly directed pressure applied from the central longitudinal lumen of the endoluminal prosthesis less than about 3.0 atmospheres.

21. A method for making an encapsulated stent-graft, comprising the steps of:

- a. concentrically engaging an endoluminal stent in a first diametric dimension about a first tubular expanded polytetrafluoroethylene member having a node and fibril microstructure in which the fibrils are oriented substantially parallel to the longitudinal axis of the tubular expanded polytetrafluoroethylene member;
- b. concentrically engaging a second tubular expanded polytetrafluoroethylene member having a node and fibril microstructure in which the fibrils are oriented substantially parallel to the longitudinal axis of the second tubular expanded polytetrafluoroethylene member, about the endoluminal stent and the first tubular expanded polytetrafluoroethylene member;

- 5
- 10
- c. applying a circumferential pressure about the first and second tubular expanded polytetrafluoroethylene members and the endoluminal stent interdisposed there between; and
  - d. exposing the first and second tubular expanded polytetrafluoroethylene members and the endoluminal stent interdisposed there between stent in its enlarged diametric state to a temperature above the crystalline melt point of polytetrafluoroethylene for a period of time sufficient to monolithically join the layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially homogeneous layer of expanded polytetrafluoroethylene.

- 15
- 20
22. The method of Claim 21, where the step (a) further comprises the steps of:
- a. providing an endoluminal stent made of a shape memory material having a pre-defined austenite tubular dimensional state and cooling the endoluminal stent to a temperature below the martensite transformation temperature of the shape memory alloy; and
  - b. deforming the endoluminal stent at a temperature below the martensite transformation temperature to a reduced diametric dimension suitable for endoluminal delivery thereof for engagement upon the first tubular polytetrafluoroethylene member.

- 25
23. The method of Claim 21, wherein the step (a) further comprises the steps of:
- a. providing a self-expanding endoluminal stent made of a material having an inherent spring tension; and
  - b. deforming the endoluminal stent to a reduced diametric dimension suitable for endoluminal delivery thereof for engagement upon the first tubular polytetrafluoroethylene member.

- 30
24. The method of Claim 21, wherein the step (a) further comprises the steps of providing an endoluminal stent made of a shape memory material having a pre-defined austenite tubular dimensional state and step (b) is performed while the endoluminal stent is at the pre-defined austenite tubular dimensional state.



25. The method of Claim 21, wherein the step (a) further comprises the steps of providing a self-expanding endoluminal stent made of a material having an inherent spring tension and the step (b) is performed while the endoluminal stent is at a radially unstrained dimensional state.

5

26. A method for making a stent-graft, comprising the steps of:

- a. transforming a shape memory endoluminal stent from a substantially austenite phase to a temperature-induced martensite phase;
- b. reducing the diametric dimension of the endoluminal stent in its temperature-induced martensite phase from a larger diametric dimension to a reduced diametric dimension;
- c. constraining the endoluminal stent in a temperature-induced martensite phase and in its reduced diametric dimension with a substantially monolithic covering of expanded polytetrafluoroethylene circumferentially covering at least a portion of the longitudinal extent of the endoluminal stent, the substantially monolithic covering of expanded polytetrafluoroethylene being radially deformable to release constraining force exerted on the endoluminal stent.

20

27. A method for making an encapsulated stent-graft, comprising the steps of:

- a. cooling an endoluminal stent made of a shape memory material and having a pre-determined austenite tubular dimensional state to a temperature below the martensite transformation temperature of the shape memory alloy;
- b. deforming the endoluminal stent at a temperature below  $M_s$  to reduce the diametric dimension of the endoluminal stent to a diameter suitable for endoluminal delivery thereof, the deformation being performed substantially without plastic deformation of the endoluminal stent;
- c. concentrically engaging the deformed endoluminal stent in its deformed martensite state about a first layer of longitudinally expanded polytetrafluoroethylene;




30

- 5
- d. concentrically engaging a second layer of longitudinally expanded polytetrafluoroethylene about the deformed endoluminal stent and the first layer of longitudinally expanded polytetrafluoroethylene;
- e. applying a circumferential pressure about the first and second layers of longitudinally expanded polytetrafluoroethylene and the deformed endoluminal stent; and
- 10
- f. exposing the first and second layers of longitudinally expanded polytetrafluoroethylene and endoluminal stent in its reduced diametric state to a temperature above the crystalline melt point of the polytetrafluoroethylene for a period of time sufficient to monolithically join the first and second layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially homogeneous layer of expanded polytetrafluoroethylene.
- 15
28. A method for making an encapsulated stent-graft, comprising the steps of:
- a. an endoluminal stent made of a pseudoelastic material and having a pre-determined austenite tubular dimensional state at a temperature above the martensite transformation temperature of the shape memory alloy;
- 20
- b. deforming the endoluminal stent at a temperature above  $A_s$  but below  $M_d$  to reduce the diametric dimension of the endoluminal stent to a diameter suitable for endoluminal delivery thereof, the deformation being performed substantially without plastic deformation of the endoluminal stent;
- 25
- c. concentrically engaging the deformed endoluminal stent in its reduced diametric state about a first layer of longitudinally expanded polytetrafluoroethylene;
- d. concentrically engaging a second layer of longitudinally expanded polytetrafluoroethylene about the deformed endoluminal stent and the first layer of longitudinally expanded polytetrafluoroethylene;
- 30
- e. applying a circumferential pressure about the first and second layers of longitudinally expanded polytetrafluoroethylene and the endoluminal stent; and

- 5 f. exposing the first and second layers of longitudinally expanded polytetrafluoroethylene and endoluminal stent in its reduced diametric state to a temperature above the crystalline melt point of the polytetrafluoroethylene for a period of time sufficient to monolithically join the first and second layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially homogeneous layer of expanded polytetrafluoroethylene.
- 10 29. A method for making an encapsulated stent-graft, comprising the steps of:
- a. concentrically engaging the endoluminal stent in its enlarged state about a first layer of longitudinally expanded polytetrafluoroethylene;
- b. concentrically engaging a second layer of longitudinally expanded polytetrafluoroethylene about the enlarged endoluminal stent and the first layer of longitudinally expanded polytetrafluoroethylene;
- 15 c. applying a circumferential pressure about the layers of longitudinally expanded polytetrafluoroethylene and the endoluminal stent; and
- d. exposing the layers of longitudinally expanded polytetrafluoroethylene locally in the void areas of the endoluminal stent in its reduced diametric state to a temperature above the crystalline melt point of the polytetrafluoroethylene for a period of time sufficient to monolithically join the first and second layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially homogeneous layer of expanded polytetrafluoroethylene in the void areas.
- 20
- 25 30. A method for making an encapsulated stent-graft, comprising the steps of:
- a. an endoluminal stent made of a pseudoelastic material and having a pre-determined austenite tubular dimensional state at a temperature above the martensite transformation temperature of the shape memory alloy ( $A_f$ );
- 30 b. deforming the endoluminal stent at a temperature above  $A_f$ , but below  $M_d$  to reduce the diametric dimension of the endoluminal stent to a diameter suitable for endoluminal delivery thereof, the deformation being

performed substantially without plastic deformation of the endoluminal stent;

- c. concentrically engaging the deformed endoluminal stent in its reduced diametric state about a first layer of longitudinally expanded polytetrafluoroethylene;
- d. concentrically engaging a second layer of longitudinally expanded polytetrafluoroethylene about the deformed endoluminal stent and the first layer of longitudinally expanded polytetrafluoroethylene;
- e. applying a circumferential pressure about the first and second layers of longitudinally expanded polytetrafluoroethylene and the endoluminal stent; and
- f. exposing the first and second layers longitudinally expanded polytetrafluoroethylene locally in the void areas of the endoluminal stent in its reduced diametric state to a temperature above the crystalline melt point of the polytetrafluoroethylene for a period of time sufficient to monolithically join the first and second layers of polytetrafluoroethylene to one another through the endoluminal stent forming a single substantially homogeneous layer of expanded polytetrafluoroethylene in the void areas.



2/4





Fig. 5





Fig. 6

3/4





Fig. 7







Fig. 8





# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/08994

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 21403 A (PROGRAFT MEDICAL INC ; GORE & ASS. (US)) 19 June 1997	1
A	see page 17, line 12 - line 26; claims 1,16,19; figures	2,3
Y	WO 96 28115 A (IMPRA INC) 19 September 1996	1
A	cited in the application see page 9, line 15 - line 21 see page 37, line 14 - line 22; claims 1,2,7; figures	2-30
A	WO 97 07751 A (IMPRA INC ; BANAS CHRISTOPHER E (US); KOWLIGI RAJAGOPAL R (US); TAN) 6 March 1997 see page 11, line 22 - line 25; figures	1-30
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 October 1998

Date of mailing of the international search report

22/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kanal, P

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/08994

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 05132 A (GORE & ASS) 23 February 1995 see claims 1,2,7,19,26,27; figures ---	1-30
A	WO 96 00103 A (ENDOMED INC ;COLONE WILLIAM M (US)) 4 January 1996 see claims 5,23,24,26,36,45; figures ---	1-30
A	EP 0 686 379 A (CARDIOVASCULAR CONCEPTS INC) 13 December 1995 see column 8, line 4 - column 9, line 15; claim 1; figures -----	1,2

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. Patent Application No

PCT/US 98/08994

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9721403	A	19-06-1997	AU 1413897 A EP 0866678 A	03-07-1997 30-09-1998
WO 9628115	A	19-09-1996	US 5749880 A CA 2215027 A EP 0814729 A	12-05-1998 19-09-1996 07-01-1998
WO 9707751	A	06-03-1997	AU 3371895 A EP 0850030 A	19-03-1997 01-07-1998
WO 9505132	A	23-02-1995	US 5735892 A AU 6824994 A CA 2167944 A EP 0714269 A JP 9501584 T US 5700285 A US 5810870 A	07-04-1998 14-03-1995 23-02-1995 05-06-1996 18-02-1997 23-12-1997 22-09-1998
WO 9600103	A	04-01-1996	CA 2193983 A EP 0767684 A JP 10506021 T	04-01-1996 16-04-1997 16-06-1998
EP 0686379	A	13-12-1995	EP 0792627 A JP 8052165 A US 5683451 A	03-09-1997 27-02-1996 04-11-1997

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: \_\_\_\_\_**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**